Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2009 Product Development Investment Cash investment in product development over five years 09 4.2m 08 3.7m 07 3.3m 06 1.6m 05 1.4m Dechra has a proven track record of delivering licensed products by working closely with regulatory authorities and by complying with the highest standards.
Increased investment in product development has been made throughout the year being reported and, following identification of new development opportunities see page 21, a further significant increase will be made in the new financial year.
04 16782 08 09 2009 Proof 9 Stock code: DPH Pharmaceuticals Services www.
com Product Development Investment 4.2 million invested in product development during 2008 2009 05 16782 08 09 2009 Proof 9 Our Accounts Our Governance Our Performance Our Business
